Treatment of prostate cancer, melanoma or hepatic cancer
First Claim
Patent Images
1. A method of treating prostate cancer, melanoma or hepatic cancer in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of the heterocyclic compound represented by Formula I:
-
or a pharmaceutically acceptable salt thereof, wherein, X represents C—
R7 wherein R7 denotes hydrogen or a halogen;
R1 and R2 independently represent hydrogen or a C1-C6 alkyl;
R3 represents;
an optionally substituted morpholino;
an optionally substituted pyrrolydinyl;
or a —
NR10R11 group, wherein R10 and R11, independently denote a C1-C6 alkyl, a hydroxy C1-C6 alkyl, a morpholino with C1-C6 alkyl;
R4 represents hydrogen, a C1-C6 alkyl, a C1-C6 alkoxy, a C1-C6 alkoxycarbonyloxy, amino, or hydroxyl;
R5 represents hydrogen, a C1-C6 alkyl, a halogen, or hydroxyl;
R6 represents;
a C1-C6 alkyl;
a hydroxy C1-C6 alkyl;
a —
CHnF3-n group wherein n denotes 1 or 2;
—
NHR12, wherein R12 denotes hydrogen or a COR13 group, wherein R13 denotes hydrogen, a C1-C6 alkyl or a C1-C6 alkoxy.
1 Assignment
0 Petitions
Accused Products
Abstract
The present application describes a method of treating prostate cancer, melanoma or hepatic cancer in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of the heterocyclic compound represented by Formula I or its pharmaceutically acceptable salt:
28 Citations
2 Claims
-
1. A method of treating prostate cancer, melanoma or hepatic cancer in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of the heterocyclic compound represented by Formula I:
or a pharmaceutically acceptable salt thereof, wherein, X represents C—
R7 wherein R7 denotes hydrogen or a halogen;
R1 and R2 independently represent hydrogen or a C1-C6 alkyl;
R3 represents;
an optionally substituted morpholino;
an optionally substituted pyrrolydinyl;
ora —
NR10R11 group, wherein R10 and R11, independently denote a C1-C6 alkyl, a hydroxy C1-C6 alkyl, a morpholino with C1-C6 alkyl;
R4 represents hydrogen, a C1-C6 alkyl, a C1-C6 alkoxy, a C1-C6 alkoxycarbonyloxy, amino, or hydroxyl;
R5 represents hydrogen, a C1-C6 alkyl, a halogen, or hydroxyl;
R6 represents;
a C1-C6 alkyl;
a hydroxy C1-C6 alkyl;
a —
CHnF3-n group wherein n denotes 1 or 2;
—
NHR12, wherein R12 denotes hydrogen or a COR13 group, wherein R13 denotes hydrogen, a C1-C6 alkyl or a C1-C6 alkoxy.- View Dependent Claims (2)
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeZenyaku Kogyo Kabushiki Kaisha
-
Original AssigneeZenyaku Kogyo Kabushiki Kaisha
-
InventorsSaitoh, Kenichi, Matsuno, Toshiyuki, Watanabe, Tetsuo, Tsuchida, Yoshio, Yaguchi, Shinichi, Koshimizu, Ichiro, Yoshimi, Hisashi
-
Application NumberUS11/404,078Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current514/232.800CPC Class CodesA61K 31/5377 not condensed and containin...
